Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 112Recurrence 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Neoplasms 14Neoplasms, Plasma Cell 13Leukemia 10Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myeloid, Acute 8Carcinoma, Non-Small-Cell Lung 8Lymphoma, Large B-Cell, Diffuse 7Burkitt Lymphoma 7Vomiting 6Prostatic Neoplasms 6Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Nausea 5Lung Neoplasms 5Pancreatic Neoplasms 3Lymphoma, Follicular 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Neoplasms 3Hematologic Diseases 3Glioblastoma 3Amyloidosis 3Smoldering Multiple Myeloma 2Renal Insufficiency 2Oligodendroglioma 2Myelodysplastic Syndromes 2

Interventions

navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Plasmacytoma × Dexamethasone × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡